Nucelion Therapeutics Pvt Ltd, a wholly owned subsidiary of Bharat Biotech International Ltd, established a Contract Research Development and Manufacturing Organisation (CRDMO) focused on cell and ...

People looking to lose weight and lower their blood sugar may someday be able to get a single injection that turns their ...

Bharat Biotech is venturing into advanced therapies by launching Nucelion Therapeutics, a subsidiary focused on cell and gene ...

Bharat Biotech expands into advanced biologics with Nucelion Therapeutics, a new CRDMO for cell and gene therapy manufacturing, positioning India as a rising hub for global biotherapeutics.

Bharat Biotech launches Nucelion Therapeutics, a CRDMO focused on advanced cell and gene therapies for global life science innovators.

Bharat Biotech launches Nucelion Therapeutics, a CRDMO in Hyderabad for advanced cell and gene therapy manufacturing and development.

Nucelion Therapeutics Pvt Ltd, a newly established Hyderabad-based Contract Research, Development, and Manufacturing Organisation (CRDMO) focused on cell and gene therapies, announced its formal ...

The partnership leverages Genenta's robust and well-tested LVV Plasmid DNA technology, a platform developed from the foundational research of Professor Luigi Naldini, co-founder of Genenta. This ...

Peripheral artery disease (PAD) is a vascular disorder caused by occlusive atherosclerosis, which commonly impairs blood flow to the lower extremities. The prevalence of PAD is increasing globally ...

The genetic culprits responsible for the spread of multidrug resistance (MDR) in bacteria have been identified by new research mapping 100 years of bacterial evolution. Experts at the Wellcome Sanger ...

The global viral vector and plasmid DNA manufacturing market size was calculated at US$ 7.26 billion in 2024 and is projected to reach around US$ 43.04 billion by 2034, expanding at a compound annual ...